NCT02628067: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

NCT02628067
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only Microsatellite Instability-High (MSI-H) tumors are eligible
Exclusions: Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT02628067

Comments are closed.

Up ↑